Omri Schanin

Synthetic biology has entered a new era of capability. AI-driven protein design, advanced cell engineering, and increasingly automated labs are rapidly expanding what is scientifically possible. Yet commercial scale and sustainable economics remain out of reach. The core challenge is no longer whether biology can be engineered, but whether it can be consistently deployed in real-world environments. Moving from lab success to industrial production introduces a new set of constraints, from process robustness and yield to infrastructure, supply chains, and cost. This session focuses on what it actually takes to translate innovation into manufacturing reality. Rather than diagnosing failure points, it highlights the systems, platforms, and partnerships that enable biology to scale. What is working today, where are the key integration bottlenecks, and how do we build a more cohesive path from design to deployment?